These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30349383)

  • 1. Clinicopathologic characteristics and clinical outcomes of pure type and mixed type of tubular carcinoma of the breast: a single-institution cohort study.
    Zhang WW; Wu SG; Ling YH; Sun JY; Long ZQ; Hua X; Dong Y; Li FY; He ZY; Lin HX
    Cancer Manag Res; 2018; 10():4509-4515. PubMed ID: 30349383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tubular carcinoma of the breast: clinicopathologic features and survival outcome compared with ductal carcinoma in situ.
    Min Y; Bae SY; Lee HC; Lee JH; Kim M; Kim J; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    J Breast Cancer; 2013 Dec; 16(4):404-9. PubMed ID: 24454462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pure and Mixed Tubular Carcinoma of the Breast: Mammographic Features, Clinicopathological Characteristics and Prognostic Analysis.
    Wen C; Xu W; Qin G; Zeng H; He Z; Wang S; Xu Z; Ma M; Luo Z; Chen W
    Technol Cancer Res Treat; 2021; 20():15330338211045198. PubMed ID: 34918991
    [No Abstract]   [Full Text] [Related]  

  • 4. Tubular carcinoma of the breast: further evidence to support its excellent prognosis.
    Rakha EA; Lee AH; Evans AJ; Menon S; Assad NY; Hodi Z; Macmillan D; Blamey RW; Ellis IO
    J Clin Oncol; 2010 Jan; 28(1):99-104. PubMed ID: 19917872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk stratification system for groups with a low, intermediate, and high risk of subsequent distant metastasis and death following isolated locoregional recurrence of breast cancer.
    Lee YJ; Park H; Kang CM; Gwark SC; Lee SB; Kim J; Chung IY; Ko BS; Kim HJ; Kim SB; Ahn SD; Gong G; Son BH; Ahn SH; Lee JW
    Breast Cancer Res Treat; 2020 Jan; 179(2):315-324. PubMed ID: 31642987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.
    Guo H; Ding Q; Gong Y; Gilcrease MZ; Zhao M; Zhao J; Sui D; Wu Y; Chen H; Liu H; Zhang J; Resetkova E; Moulder SL; Wang WL; Huo L
    Breast Cancer Res; 2020 Jun; 22(1):69. PubMed ID: 32576238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and long-term survival of patients diagnosed with pure tubular carcinoma of the breast.
    Poirier É; Desbiens C; Poirier B; Boudreau D; Jacob S; Lemieux J; Doyle C; Diorio C; Hogue JC; Provencher L
    J Surg Oncol; 2018 May; 117(6):1137-1143. PubMed ID: 29205352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Well-differentiated (tubular) carcinoma of the breast. A clinicopathologic study of 145 pure and mixed cases.
    Deos PH; Norris HJ
    Am J Clin Pathol; 1982 Jul; 78(1):1-7. PubMed ID: 6285690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive micropapillary carcinoma of the breast: a clinicopathologic study of 103 cases of an unusual and highly aggressive variant of breast carcinoma.
    Gokce H; Durak MG; Akin MM; Canda T; Balci P; Ellidokuz H; Demirkan B; Gorken IB; Sevinc AI; Kocdor MA; Saydam S; Harmancioglu O
    Breast J; 2013; 19(4):374-81. PubMed ID: 23714006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in Prognostic Factors and Failure Patterns Between Invasive Micropapillary Carcinoma and Carcinoma With Micropapillary Component Versus Invasive Ductal Carcinoma of the Breast: Retrospective Multicenter Case-Control Study (KROG 13-06).
    Yu JI; Choi DH; Huh SJ; Cho EY; Kim K; Chie EK; Ha SW; Park IA; Ahn SJ; Lee JS; Shin KH; Kwon Y; Kim YB; Suh CO; Koo JS; Kim JH; Jeong BG; Kim IA; Lee JH; Park W
    Clin Breast Cancer; 2015 Oct; 15(5):353-61.e1-2. PubMed ID: 25776197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omission of Postoperative Radiotherapy in Women Aged 65 Years or Older With Tubular Carcinoma of the Breast After Breast-Conserving Surgery.
    Wu SG; Zhang WW; Sun JY; Li FY; Chen YX; He ZY
    Front Oncol; 2018; 8():190. PubMed ID: 29900127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical-pathologic features and long-term outcomes of tubular carcinoma of the breast compared with invasive ductal carcinoma treated with breast conservation therapy.
    Liu GF; Yang Q; Haffty BG; Moran MS
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1304-8. PubMed ID: 19386432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Locoregional recurrence following nipple-sparing mastectomy with immediate breast reconstruction: Patterns and prognostic significance.
    Wu ZY; Han HH; Kim HJ; Lee J; Chung IY; Kim J; Lee S; Han J; Eom JS; Kim SB; Gong G; Kim HH; Son BH; Ahn SH; Ko B
    Eur J Surg Oncol; 2021 Jun; 47(6):1309-1315. PubMed ID: 33495030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up.
    Turashvili G; Brogi E; Morrow M; Dickler M; Norton L; Hudis C; Wen HY
    BMC Cancer; 2018 Jan; 18(1):42. PubMed ID: 29304773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probability of axillary node involvement in patients with tubular carcinoma of the breast.
    Papadatos G; Rangan AM; Psarianos T; Ung O; Taylor R; Boyages J
    Br J Surg; 2001 Jun; 88(6):860-4. PubMed ID: 11412259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive micropapillary carcinoma of the breast had poor clinical characteristics but showed no difference in prognosis compared with invasive ductal carcinoma.
    Li G; Yang S; Yao J; Wang Z; Yao G; Liu M; Ye C
    World J Surg Oncol; 2016 Aug; 14(1):207. PubMed ID: 27492008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tubular carcinoma of the breast: institutional and SEER database analysis supporting a unique classification.
    Romano AM; Wages NA; Smolkin M; Fortune KL; Atkins K; Dillon PM
    Breast Dis; 2015; 35(2):103-11. PubMed ID: 25567000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of ductal carcinoma in situ component in invasive ductal carcinoma of the breast: a Surveillance, Epidemiology, and End Results database analysis.
    Wu SG; Zhang WW; Sun JY; He ZY
    Cancer Manag Res; 2018; 10():527-534. PubMed ID: 29593431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy.
    Chun JW; Kim J; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH; Ahn SH; Lee SB
    Sci Rep; 2021 Apr; 11(1):9056. PubMed ID: 33907236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
    Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
    Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.